-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)
24 Février 2010 - 3:01PM
Edgar (US Regulatory)
|
|
|
OMB Number:
|
|
3235-0080
|
Expires:
|
|
January 31, 2012
|
Estimated average burden
hours per response. . .
|
|
1.00
|
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 0-23930
Issuer: Targeted Genetics Corporation
Exchange:
NASDAQ Stock Market, LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is
listed and/or registered)
1100 Olive Way, Suite 100, Seattle, Washington 98101; (206) 623-7612
(Address, including zip code, and telephone number, including area code, of Issuers principal executive offices)
Common Stock, $0.01 par value
(Description of class of securities)
Please place an X in the box to designate the rule
provision relied upon to strike the class of securities from listing and registration:
|
¨
|
17 CFR 240.12d2-2(a)(1)
|
|
¨
|
17 CFR 240.12d2-2(a)(2)
|
|
¨
|
17 CFR 240.12d2-2(a)(3)
|
|
¨
|
17 CFR 240.12d2-2(a)(4)
|
|
¨
|
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
|
|
x
|
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the
voluntary withdrawal of the class of securities from listing and registration on the Exchange.
|
Pursuant to the requirements of
the Securities Exchange Act of 1934, Targeted Genetics Corporation certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the
undersigned duly authorized person.
|
|
|
|
|
|
|
February 24, 2010
|
|
By
|
|
/s/ David J. Poston
|
|
Vice President, Finance and
Chief Financial Officer
|
Date
|
|
Name:
|
|
David J. Poston
|
|
Title
|
1
|
Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
|
Tecogen (QX) (USOTC:TGEN)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Tecogen (QX) (USOTC:TGEN)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Tecogen Inc (QX) (OTCMarkets): 0 recent articles
Plus d'articles sur Targeted Genetics Corp (OTC)